Zenapax vial 25 mg 5ml

Description

Zenapax is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants.

Detailed Description:

Zenapax is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.

General Information :
Hoffman-La Roche’s new monoclonal antibody drug, Zenapax (daclizumab), has been approved to prevent rejection of kidney transplants. The drug uses the body’s own immune system to prevent the acute rejection that can make kidney transplants fail.
Clinical Results. It is marketed by Hoffman La Roche pharmaceuticals.

The FDA said its approval was based on two clinical trials that showed Zenapax significantly reduced acute rejections in patients who got the drug along with the standard three-drug cocktail of immunosuppressant drugs. Patients on Zenapax had 37 to 40% fewer rejections episodes than those given an inert placebo.

Additional Information

Side Effects

Pack Size

3S Corporation is a WHO GDSP approved & licensed Pharmaceutical stockist/wholesaler/distributor/exporter/importer of Zenapax vial 25 mg 5ml based in India - To buy Zenapax vial 25 mg 5ml or know its cost price contact us here.

We supply & sell Zenapax vial 25 mg 5ml for Reference Listed Drugs, Government Tenders, Shortage Lists, Emergency Imports, Name Patient Drugs, Comparator Drug Studies, Un-licensed Importation, clinical trial samples & Bio-Similars.

You might also like or love to try

Acalabrutinib 100 mg Capsule

Remdesivir 100 mg Injection

Erleada 60 mg Tablets

Disclaimer: All trademarks, logos and brand names are the property of their respective owners, used here solely for identification & reference only under Section 30(1) of the Trade Marks Act, 1999. We are not affiliated with or endorsed by them unless explicitly stated. By using this website, you agree to these terms.